Diabetic cardiomyopathy
Diabetic cardiomyopathy is defined by the existence of abnormal myocardial structure and performance in the absence of other cardiac risk factors, such as coronary artery disease, hypertension, and significant valvular disease, in individuals with diabetes mellitus.
- AstraZeneca’s Onglyza (saxagliptin)
- AstraZeneca’s Kombiglyze (saxagliptin and metformin extended release)
- Takeda’s Nesina (alogliptin)
- Takeda’s Kazano (alogliptin and metformin)
- Takeda’s Oseni (alogliptin and pioglitazone)
Related Conference of Diabetic cardiomyopathy
July 23-24, 2026
13th International Conference on Geriatric Cardiology, Cardiovascular Diseases and Palliative Care
Paris, France
July 27-28, 2026
9th International Conference on Cardiovascular Diseases and Therapeutics
Amsterdam, Netherlands
October 22-23, 2026
34th International Congress on Cardiology and Medical Interventions
Toronto, Canada
December 17-18, 2026
13th World Congress on Hypertension, Cardiology, Primary Health and Patient Care
Paris, France